ZBH
ChallengerZimmer Biomet
$95.34
+2.35%
as of 13 Apr
Power Core
Power Core in one sentence: Zimmer Biomet's moat is the deep institutional entrenchment of its implant systems within hospital surgical programs, sustained by surgeon training relationships and a broad product portfolio that creates switching costs at the procedural level.
Direction of Movement
Lateral Trajectory With Conditional Upward Optionality
ROC 200
-1.4%
ZBH
Zimmer Biomet
$95.34
+2.35%
as of 13 Apr
DCF Fair Value: $422.63
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.
Company Profile
Zimmer Biomet Holdings, Inc. is a global medical technology company that designs, manufactures, and markets orthopedic reconstructive products for joint replacement and repair. The company provides a comprehensive portfolio including knee and hip implants, sports medicine and biologics products, extremities and trauma solutions, craniomaxillofacial and thoracic reconstructive products, spine implants, office-based surgical technologies, and dental implants. Zimmer Biomet serves patients, surgeons, and healthcare systems across multiple geographical markets including the Americas, Europe, Middle East, Africa, and Asia Pacific regions. The company has pursued strategic acquisitions and divestitures to strengthen its product lineup and expand its pipeline, demonstrating commitment to innovation in orthopedic solutions. With recent advancements including robotic-assisted surgical systems and iodine-treated implant technologies, Zimmer Biomet maintains a significant presence in the orthopedic reconstructive market. Founded in 1927 and headquartered in Warsaw, Indiana, the company operates as a key player in the medical device industry, focusing on improving musculoskeletal health outcomes globally.